| GRFT + |
CI at varying HIV inhibition |
Effectb |
| 50% |
75% |
95% |
| b12 mAb |
0.84 ± 0.16 |
0.72 ± 0.11 |
0.66 ± 0.12 |
+++ |
| 2F5 mAb |
1.02 ± 0.10 |
0.85 ± 0.10 |
0.80 ± 0.20 |
++ |
| 2G12 mAb |
N.A.a |
N.A.a |
N.A.a |
N.A.a |
| AMD3100 |
0.60 ± 0.14 |
0.48 ± 0.12 |
0.46 ± 0.09 |
+++ |
| BanLec |
0.88 ± 0.02 |
0.79 ± 0.12 |
0.98 ± 0.09 |
Additivity |
| T20 |
0.97 ± 0.08 |
0.72 ± 0.05 |
0.55 ± 0.05 |
+++ |
| PRO2000 |
0.75 ± 0.11 |
0.72 ± 0.11 |
0.78 ± 0.17 |
++ |
aN.A.: not applicable
bEffect of drug interaction based at CI95%, whereby CI<0.9 are synergistic; 0.9<CI<1.1 are additive and CI>1.1 are antagonistic. The degree of synergy: 0.85<CI<0.9: + (slight
synergy); 0.7<CI<0.85: ++ (moderate synergy); 0.3<CI<0.7: +++ (synergy); 0.1<0.3: ++++ (potent synergy). |
